Literature DB >> 29276273

Drug Monographs: Avelumab and Ribociclib.

J Aubrey Waddell1, Dominic A Solimando2.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, email: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2017        PMID： 29276273      PMCID： PMC5735717          DOI： 10.1177/0018578717719183

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  7 in total

1.  Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.

Authors:  Howard L Kaufman; Jeffery Russell; Omid Hamid; Shailender Bhatia; Patrick Terheyden; Sandra P D'Angelo; Kent C Shih; Céleste Lebbé; Gerald P Linette; Michele Milella; Isaac Brownell; Karl D Lewis; Jochen H Lorch; Kevin Chin; Lisa Mahnke; Anja von Heydebreck; Jean-Marie Cuillerot; Paul Nghiem
Journal:  Lancet Oncol       Date:  2016-09-01       Impact factor: 41.316

2.  Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.

Authors:  James L Gulley; Arun Rajan; David R Spigel; Nicholas Iannotti; Jason Chandler; Deborah J L Wong; Joseph Leach; W Jeff Edenfield; Ding Wang; Hans Juergen Grote; Anja von Heydebreck; Kevin Chin; Jean-Marie Cuillerot; Karen Kelly
Journal:  Lancet Oncol       Date:  2017-03-31       Impact factor: 41.316

3.  Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.

Authors:  Christopher R Heery; Geraldine O'Sullivan-Coyne; Ravi A Madan; Lisa Cordes; Arun Rajan; Myrna Rauckhorst; Elizabeth Lamping; Israel Oyelakin; Jennifer L Marté; Lauren M Lepone; Renee N Donahue; Italia Grenga; Jean-Marie Cuillerot; Berend Neuteboom; Anja von Heydebreck; Kevin Chin; Jeffrey Schlom; James L Gulley
Journal:  Lancet Oncol       Date:  2017-03-31       Impact factor: 41.316

4.  Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.

Authors:  G Curigliano; P Gómez Pardo; F Meric-Bernstam; P Conte; M P Lolkema; J T Beck; A Bardia; M Martínez García; F Penault-Llorca; S Dhuria; Z Tang; N Solovieff; M Miller; E Di Tomaso; S A Hurvitz
Journal:  Breast       Date:  2016-06-20       Impact factor: 4.380

5.  A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.

Authors:  Jeffrey R Infante; Philippe A Cassier; John F Gerecitano; Petronella O Witteveen; Rashmi Chugh; Vincent Ribrag; Abhijit Chakraborty; Alessandro Matano; Jason R Dobson; Adam S Crystal; Sudha Parasuraman; Geoffrey I Shapiro
Journal:  Clin Cancer Res       Date:  2016-08-19       Impact factor: 12.531

6.  Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

Authors:  Gabriel N Hortobagyi; Salomon M Stemmer; Howard A Burris; Yoon-Sim Yap; Gabe S Sonke; Shani Paluch-Shimon; Mario Campone; Kimberly L Blackwell; Fabrice André; Eric P Winer; Wolfgang Janni; Sunil Verma; Pierfranco Conte; Carlos L Arteaga; David A Cameron; Katarina Petrakova; Lowell L Hart; Cristian Villanueva; Arlene Chan; Erik Jakobsen; Arnd Nusch; Olga Burdaeva; Eva-Maria Grischke; Emilio Alba; Erik Wist; Norbert Marschner; Anne M Favret; Denise Yardley; Thomas Bachelot; Ling-Ming Tseng; Sibel Blau; Fengjuan Xuan; Farida Souami; Michelle Miller; Caroline Germa; Samit Hirawat; Joyce O'Shaughnessy
Journal:  N Engl J Med       Date:  2016-10-07       Impact factor: 91.245

7.  Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.

Authors:  Andrea B Apolo; Jeffrey R Infante; Ani Balmanoukian; Manish R Patel; Ding Wang; Karen Kelly; Anthony E Mega; Carolyn D Britten; Alain Ravaud; Alain C Mita; Howard Safran; Thomas E Stinchcombe; Marko Srdanov; Arnold B Gelb; Michael Schlichting; Kevin Chin; James L Gulley
Journal:  J Clin Oncol       Date:  2017-04-04       Impact factor: 44.544
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.